Stockwinners Market Radar for November 20, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST Tharimmune Inc trading halted, news pending

18:47 EST Seaport Global Acquisition II terminates merger plan with American Battery - Seaport Global Acquisition II announced that it has terminated the previously announced agreement and plan of merger with American Battery Materials. The Company also announced today that, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation, as amended, the Company intends to dissolve and liquidate in accordance with the provisions of the Amended Charter. As a result, the Company will redeem all of the remaining outstanding shares of Class A common stock that were included in the units issued in its initial public offering at a per-share redemption price of approximately $10.78 as of November 16. In order to provide for the disbursement of funds from the trust account, the Company will instruct the trustee of the trust account to take all necessary actions to liquidate the securities held in the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. The Company's sponsor has agreed to waive its redemption rights with respect to its outstanding shares of Class A common. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless.

17:24 EST Zoom Video sees FY24 free cash flow $1.34-$1.35B - Says Zoom phone reached 7M paid seats. Says reached approximately 700 contract center customers. Says had 219,700 enterprise customers in Q3. Says had 3,731 customers contributing more than $100,000 in trailing 12 months revenue. Says online average monthly churn of 3%. Says in Q4 expects deferred revenue to be down 6%-8%. Says renewal seasonality peaks in Q1. Comments and guidance taken from Q3 earnings conference call.

17:03 EST Fisker receives notice of late filing from NYSE - Fisker announced that it received a notice from the New York Stock Exchange on November 16, 2023 indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission. The NYSE informed the Company that, under NYSE rules, the Company will have six months from November 14, 2023 to file the Form 10-Q with the SEC. The company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-Q. If the company fails to file the Form 10-Q before the NYSE's compliance deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the company to regain compliance, depending on the specific circumstances. The notice from the NYSE also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant.

17:00 EST Morphosys Ag (ADR) trading resumes

16:48 EST Aerovate completes enrollment for Phase 2b portion of IMPAHCT study - Aerovate Therapeutics announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial, or IMPAHCT, Phase 2b/Phase 3 study evaluating AV-101, a novel dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, has completed enrollment at 202 adult patients. Aerovate expects to report topline data from the Phase 2b portion of the trial in June 2024. In addition, the first patient has been enrolled in the Phase 3 portion of IMPAHCT. IMPAHCT is a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled multi-national trial evaluating the safety, efficacy, tolerability, pharmacokinetics (PK) and pharmacodynamics of AV-101 in adults with PAH. The IMPAHCT trial was structured with a seamless adaptive Phase 2b/Phase 3 design to allow for an efficient development timeline, thus enabling the immediate enrollment of patients in the Phase 3 portion of the study upon the completion of enrollment in the Phase 2b portion. Currently, more than 120 sites are open and actively recruiting patients in the Phase 3 portion of the trial. The Phase 2b primary endpoint of IMPAHCT is the placebo corrected change from baseline in pulmonary vascular resistance (PVR). Following the results of the Phase 2b portion of the study, an optimal dose will be selected and all subsequent patients enrolled in IMPAHCT will be randomized to either placebo or the optimal dose. The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk distance after 24 weeks of treatment with the optimal dose.

16:37 EST Frequency Electronics awarded $19M from U.S. aerospace prime contractor - Frequency Electronics announced a contract award of approximately $19M from a major U.S. aerospace prime contractor to supply on-board precision frequency-generation systems for a multi satellite program. Under this contract, FEI will develop, manufacture, test and deliver within 24 months, state-of-the-art frequency generators and microwave synthesizers. The systems will provide multiple microwave frequencies for the spacecraft platforms within which they are deployed, and enhance their mission effectiveness. This high-performance hardware is derived from similar models that FEI has provided in the past for U.S. Government satellites, and which are successfully operating in orbit.

16:35 EST Riskified receives Israeli court approval for $75M share repurchase program - Riskified announced that it has received approval from the Tel Aviv District Court Economic Department to implement its previously announced share repurchase program, pursuant to which the Company may repurchase up to $75M of its ordinary shares. The Israeli Court approval is valid through May 19, 2024. The Company may file extension requests with the Israeli Court on an ongoing basis as required. Eido Gal, Chief Executive Officer, stated: "We are pleased to announce that the Israeli Court has approved our Repurchase Program. We expect to leverage this program to take advantage of attractive repurchasing opportunities and to manage share dilution. Our strong balance sheet enables us to continue investing in the growth of the business, while simultaneously driving shareholder value by executing this Repurchase Program."

16:31 EST Kazia Therapeutics receives non-compliance letter from NASDAQ - Kazia Therapeutics received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market, dated November 20, notifying the company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Capital Market's rules for continued listing. The deficiency notification has no immediate impact on the company's operations or listing. Kazia's securities will continue to trade as normal on Nasdaq Capital Market under the ticker KZIA. Nasdaq Listing Rule 5550 requires listed securities to maintain a minimum bid price of at least US$ 1.00 per share, and failure to do so for a period of 30 consecutive business days triggers a deficiency notice. Based on the closing bid price of Kazia's American Depository Shares, each representing ten ordinary shares of the company, for the period from October 2 to November 17 the company no longer met this requirement as of November 17. The company will closely monitor the situation and intends to resolve the deficiency and regain compliance with the Nasdaq Listing Rules.

16:24 EST Morphosys Ag (ADR) trading halted, news pending

16:17 EST Lumen extends its NOL Rights Plan - Lumen Technologies announced that its board of directors has unanimously approved the amendment and restatement of its Section 382 Rights Agreement to, among other things, extend its expiration date from December 1, 2023 to December 1, 2026. The company has extended its NOL Rights Plan through December 1, 2026 to protect its federal net operating loss carryforwards of approximately $1B as of December 31, 2022, which, if available, can be used to reduce its future payments of U.S. federal income taxes. The NOL Rights Plan, as amended, was approved by the company's shareholders at its 2021 Annual Meeting of Shareholders by approximately 90% of the votes cast. The company intends to submit the amendment and restatement of the NOL Rights Plan for ratification by the company's shareholders at its 2024 Annual Meeting of Shareholders. If shareholder ratification is not obtained by December 1, 2024, the NOL Rights Plan will terminate on such date, if not earlier terminated as provided therein.

16:17 EST TechnipFMC to sell Measurement Solutions Business for $205M in cash - TechnipFMC announced an agreement to sell the company's Measurement Solutions business to One Equity Partners for $205M in cash, subject to customary adjustments at the closing of the transaction. As part of the Surface Technologies segment, the Measurement Solutions business encompasses terminal management solutions and metering products and systems, and includes engineering and manufacturing locations in North America and Europe. Doug Pferdehirt, Chair and Chief Executive Officer at TechnipFMC, commented: "This transaction reflects TechnipFMC's broader portfolio strategy to further focus on our core products and market-leading technologies, as well as integrated solutions and services for our clients." The transaction is expected to close during the first half of 2024 and is subject to customary closing conditions. The company will work closely with One Equity Partners to ensure a smooth transition of business activities.

16:11 EST Home Depot to acquire International Designs Group, terms not disclosed - The Home Depot has entered into a definitive agreement to acquire International Designs Group, a platform company that owns and operates Construction Resources and other design-oriented subsidiaries. Construction Resources is a leading distributor of design-oriented surfaces, appliances and architectural specialty products for professional contractors focused on renovation, remodeling, residential home building and multi-family. The Home Depot agreed to acquire IDG from Mill Point Capital LLC, a private equity firm focused on control-oriented investments in the business services, industrials and IT services sectors. The acquisition is expected to close by the end of 2023.

16:10 EST ICF International and U.S. HUD announce cooperative agreements - The U.S. Department of Housing and Development, or HUD, recently awarded global consulting and technology services provider ICF several new cooperative agreements to provide community development and advanced technology and analytics services to its Community Compass program. The combined agreements, which were awarded in the Q3, have a multimillion-dollar value and a term of three years. ICF's housing, disaster management, climate and technology experts will partner with HUD to provide technical assistance, training, data analysis and more to help cities, counties, states and nonprofits nationwide build capacity to implement effective community development programs, prevent and end homelessness, and secure stable, resilient and sustainable housing. The company will also continue to manage HUD Exchange, the agency's cloud-based platform that provides resources and assistance to HUD's community partners. This includes applying human-centered design to enhance the user experience and modernizing training.

16:01 EST Erayak Power Solution receives non-compliance letter from NASDAQ - Erayak Power Solution Group announced that on November 15 the Company received a letter from the Nasdaq Listing Qualifications, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share. Pursuant to Nasdaq Listing Rule 5810 the Company has been granted a 180-calendar day compliance period, or until May 13, 2024, to regain compliance with the minimum bid price requirement. If at any time during such 180-day period the closing bid price of the Company's shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance.

15:15 EST Johnson Controls awarded $33M DOE grant - Johnson Controls has been awarded a $33M grant from the U.S. Department of Energy's Office of Manufacturing and Energy Supply Chains to help increase domestic production of electric heat pumps by expanding three U.S.-based manufacturing sites. Combined, these facilities will be able to produce approximately 200,000 electric heat pumps per year, representing a nearly 200% production increase. This substantial volume will help drive energy affordability and energy security, while helping combat climate change and creating new jobs.

14:15 EST FiscalNote says Hwang held initial talks with board on potential go-private bid - In a regulatory filing from Friday, FiscalNote disclosed that on November 9, Timothy Hwang held initial discussions with certain senior management members and the board of directors regarding his interest in putting together a consortium to explore a potential go-private transaction. "Hwang has not yet provided any specific proposal, and there can be no assurance that one will be made. As a result, the Board established a special committee of the Board to evaluate, together with its advisors, any proposal it receives from Mr. Hwang regarding such a transaction, as well as any other transaction proposals that may be submitted to the Issuer. Mr. Hwang has confirmed that he will condition any proposed go-private transaction on approval of the transaction by the Special Committee and a majority of the unaffiliated stockholders of the Issuer. There can be no assurance that the foregoing will result in any transaction or any other strategic change or outcome, or as to the timing of any of the foregoing," the filing stated. In Monday afternoon trading following Friday's disclosure, shares of FiscalNote are up 20c, or 25% to $1.005. Reference Link

12:00 EST Scor ADR falls -5.2% - Scor ADR is down -5.2%, or -$1.01 to $18.18.

12:00 EST Allurion Technologies falls -12.0% - Allurion Technologies is down -12.0%, or -51c to $3.75.

12:00 EST Banco Macro rises 27.6% - Banco Macro is up 27.6%, or $5.59 to $25.83.

11:57 EST Re/Max settlement granted preliminary approval in antitrust lawsuits - Re/Max announced the Missouri court granted preliminary approval of its settlement in the class action lawsuits known as Burnett, Moehrl and Nosalek, and any similar claims on a nationwide basis. "announced the Missouri court granted preliminary approval of its settlement in the class action lawsuits known as Burnett, Moehrl and Nosalek, and any similar claims on a nationwide basis. To address the pending litigation and mitigate the uncertainties and costs associated with prolonged legal proceedings, RE/MAX, LLC entered into a settlement agreement with plaintiffs on October 5, 2023. RE/MAX, LLC agreed to pay $55 million and make changes to business practices as part of the settlement. The proposed settlement would resolve on a nationwide basis all claims asserted against RE/MAX, LLC and includes releases for all U.S. RE/MAX independent regions, franchisees and agents. RE/MAX, LLC continues to deny the allegations made in the complaints and does not acknowledge any wrongdoing. Under the terms of the proposed settlement, RE/MAX, LLC has deposited 25% of the agreed-upon $55M into a settlement fund; 25% is due within 10 business days after preliminary approval; and the remainder within 10 business days after final court approval. "We are pleased with the court's decision to grant preliminary approval of the settlement," said Nick Bailey, President and CEO of RE/MAX, LLC. "This development signifies progress in our ongoing efforts and commitment to a resolution - it's a positive step forward in bringing these cases closer to the finish line." If the settlement is granted final approval by the Missouri court, all U.S. RE/MAX affiliates, including franchisees and agents, will be protected from claims connected to the lawsuits and any similar claims. At this time, final approval is expected sometime next year. The business practice terms of the settlement must be implemented within six months of the final effective date. Apart from the $55 million payment, RE/MAX, LLC does not expect the terms of the settlement agreement to have a material impact on its results of operations and cash flows.

11:41 EST Anywhere Real Estate reports preliminary court approval of nationwide settlement - Anywhere Real Estate, formerly known as Realogy Holdings Corp., announced the company has received preliminary court approval of its nationwide agreement to settle all claims asserted or which could have been asserted against Anywhere in the Burnett, Moehrl, and Nosalek antitrust class action litigation. Preliminary approval of the settlement, the terms of which were announced in October 2023, certifies the Settlement Class and authorizes commencement of the notice period to potential class members. On or before December 22, 2023, parties must contact the court to schedule the final approval hearing, which the company still expects to occur in mid-2024. In the settlement, Anywhere agreed to provide monetary relief of $83.5M, substantially in line with the company's financial planning, as well as injunctive relief. The proposed settlement is not an admission of liability, nor does it concede or validate any of the claims asserted against Anywhere. Following final court approval, the nationwide settlement will release the company, all subsidiaries, brands, affiliated agents, and franchisees from ongoing and future litigation surrounding the antitrust claims, including the October 31, 2023, jury verdict in the Burnett class action suit. "I am pleased the court has granted Anywhere preliminary approval of our nationwide settlement. Our efforts to resolve these claims remove future uncertainty and legal expense for Anywhere, our franchisees, and affiliated agents as, together, we focus on serving home buyers and sellers as they move to what's next," said Ryan Schneider, Anywhere CEO and president.

11:26 EST Beyond holder JAT demands to inspect books - JAT Capital Master Fund, which identifies itself as the record owner of 1,000 shares of Beyond and the beneficial owner of an additional 836,397 shares, demands that the company permit JAT to inspect certain books and records of the company pursuant to Section 220 of the Delaware General Corporation Law, it was revealed in a regulatory filing. Reference Link

11:06 EST Amazon aiming to provide free AI skills training to 2M people by 2025 - Amazon has announced its "AI Ready," a new commitment designed to provide free AI skills training to 2M people globally by 2025. To achieve this goal, the company is launching new initiatives for adults and young learners, and scaling its existing free AI training programs -- removing cost as a barrier to accessing these critical skills, said Swami Sivasubramanian, Vice President of Data and AI at AWS. The three new initiatives include eight new and free AI and generative AI courses; Amazon Web Services Generative AI Scholarship, providing more than 50,000 high school and university students globally with access to a new generative AI course on Udacity; new collaboration with Code.org designed to help students learn about generative AI. The e-commerce giant also said that to support professionals in the workplace, it is announcing eight new, free AI and generative AI courses open to anyone and aligned to in-demand jobs. These courses augment the 80+ free and low-cost AI and generative AI courses and resources provided through AWS. Through the AWS Generative AI Scholarship, AWS will also provide Udacity scholarships, valued at more than $12M, to more than 50,000 high school and university students from underserved and underrepresented communities globally. Reference Link

10:00 EST Studio City falls -8.2% - Studio City is down -8.2%, or -40c to $4.50.

10:00 EST Pampa Energia rises 24.5% - Pampa Energia is up 24.5%, or $9.07 to $46.13.

10:00 EST YPF rises 41.6% - YPF is up 41.6%, or $4.47 to $15.20.

09:52 EST Guided Therapeutics reports completion of study for Chinese regulatory approval - Guided Therapeutics announced the completion of the clinical trial for marketing and sales approval of the Company's LuViva Advanced Cervical Scan by the Chinese National Medical Products Administration. The study, which included approximately 450 women, was conducted at four prestigious medical institutions, including Shandong University, Fudan University and Peking University. The study was led by Professor Dr. Kong Beihua of Qilu Hospital at Shandong University and Dr. Sui Long, Director of the Gynecology Hospital at Fudan University. Professor Kong is Vice Chairman of the Chinese Society of Obstetrics and Gynecology Society. The company's Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation intends to analyze the study results with the participating doctors and file them with the NMPA within the next 90 days. The filing triggers purchase order payments to Guided Therapeutics of approximately $2.2M, with additional significant orders for devices and disposables in 2024 and beyond. "We are extremely pleased that the study has reached its completion, and that its results will be filed soon with NMPA," said Mark Faupel, CEO of Guided Therapeutics. "We look forward to starting commercialization of LuViva in China in the near future."

09:49 EST Knightscope announces two expansion sales - Knightscope announces two new expansion sales - one for its K5 Autonomous Security Robot and one for the K1 Call Box. A Kansas City, KS casino will become the 8th property to deploy the K5 ASR under a larger master agreement announced in September with an entertainment company and operator of integrated entertainment, sports content, and casinos that enabled corporatewide expansion of Knightscope technologies to 43 properties across the United States. Additionally, a riverside park in New York currently under redevelopment construction will be adding another K1 Call Box to expand access to direct access to emergency services for people visiting the park who may be experiencing danger, a crisis or some form of distress.

09:47 EST Allurion Technologies falls -7.0% - Allurion Technologies is down -7.0%, or -30c to $3.96.

09:47 EST Transportadora de Gas del Sur SA rises 19.4% - Transportadora de Gas del Sur SA is up 19.4%, or $2.03 to $12.49.

09:47 EST YPF rises 26.7% - YPF is up 26.7%, or $2.87 to $13.60.

09:32 EST Royalty Management Holding Corp trading halted, volatility trading pause

09:31 EST Eltek receives five purchase orders totaling $3.8M - Eltek announced that it has received five purchase orders in a total amount of $3.8M. The orders are in connection with two projects for a customer. Most of the orders will be supplied by Eltek during 2024.

09:17 EST Janover acquires SaaS platform Groundbreaker, terms not disclosed - Janover has acquired Groundbreaker Technologies, a profitable Software-as-a-Service platform for commercial property professionals to raise equity capital and manage investors through an easy-to-use fintech portal. Groundbreaker is a specialized SaaS platform designed to simplify capital fundraising and investment administration in the commercial real estate industry. By offering an intuitive portal, it enables real estate professionals to efficiently manage equity capital, investor relations, and document sharing, fostering a seamless and professional investment experience. The platform also facilitates secure financial transactions and offers robust customer relationship management tools, aiming to enhance transparency and engagement between property developers and investors.

09:15 EST Siyata Mobile says 'number one' goal is cashflow positivity by mid-2024 - Siyata Mobile published a Thanksgiving Message from Marc Seelenfreund, CEO, which read in part, "Siyata's vertical strategy includes expanding our sales network and product lines. Our goal of reaching profitability in the upcoming quarters is powered by the transition from nonstock to stock status with one of the top three domestic carriers, an achievement that most devices do not attain. To this end, our products are now carried by all the major US cellphone carriers and our international footprint is growing. In fact, Siyata is the smallest company, by far, that will have a stocked device at a major mobile carrier and the benefits are massive. Until recently, our products were ordered through the carriers and the purchaser had to pay full price up front for the delivery of our first responder equipment, putting us at a price disadvantage in a highly competitive market. The SD7 handset will move from a device with a $400 MSRP to becoming a cobranded device that benefits from the carrier's subsidization program, where the unit only runs 99-cents upfront, with the balance factored into the monthly bill. Plus, our sales team is training that carrier's sales force about our Push-to-talk unit. We plan to garner additional support from our carrier partners and bring what we believe are the most rugged, reliable first responder communications products in the world today. Our goal is to be boxed and stocked by all the carriers at some point, which should greatly increase our sales directly from the carriers and expand our agency and business-to-business sales. In addition, it will make it much easier for the launch of our upcoming SD7+ which is our all-in-one bodycam push to talk communicator to gain sales traction after its upcoming 2024 launch. Our success created some growing pains this year, as is often the case for companies undergoing rapid growth, and the company raised capital to help facilitate increasing upcoming orders. We currently pay for all of our inventory upfront and our capital needs increased with these orders. Our number one goal is to be cashflow positive by mid-2024 and we will have created significant shareholder value along the way. We have multiple catalysts that we believe will help achieve our long-term approach to building shareholder equity. 1. Continued increase in US and International orders for our equipment. 2. Siyata Real Time View and SD7+ will open up to more first responder markets. 3. We hope to secure purchase order financing to facilitate our inventory needs going forward. 4. We hope to increase our partnerships with the largest carriers, transitioning all of them to cobrand Siyata Mobile products. 5. We hope to increase our sales and strategic relationships to continue bringing the best first responder communications devices in the world to the market. We believe these catalysts are crucial to our upcoming success and future shareholder value. We will continue to do what's best for the company, while delivering on our core executables so we can continue our growth strategy deliver for our customers and stakeholders."

09:05 EST SpringBig announces the launch of 'Gift Cards by Springbig' - SpringBig announced the launch of Gift Cards by Springbig. The new feature builds on recent product launches across the platform to revolutionize the way customers engage with retailers through secure, user-friendly, and efficient payment solutions. Springbig is paving the way for a future where dispensary transactions are easier and more convenient than ever. "An increasing number of consumers today are prioritizing convenience, often in the palm of their hand and on their smartphone," said Jeffrey Harris, CEO of Springbig. "Gift Cards by Springbig is doing just that by simplifying the payments process and enhancing accessibility. Much like the user-friendly functionality of the Starbucks app, Springbig's new gift card feature is empowering retailers to meet consumers where they're at through seamless digital channels."

09:04 EST LPL Financial: The Warter Group joins broker-dealer, RIA, custodial platforms - LPL Financial announced that Matt Warter, AIF and Theresa Houle, AIF, have joined LPL Financial's broker-dealer, RIA and custodial platforms, aligned with Seapoint Wealth Advisors, an existing firm supported by LPL Strategic Wealth Services. Warter and Houle reported having served $100 million in advisory, brokerage and retirement plan assets. They join LPL from Plan Member.

09:03 EST SenesTech expands distribution with DIY Pest Control through Evolve order - SenesTech has renewed and expanded its distribution with DIY Pest Control with a stocking order for Evolve Soft Bait, a soft bait product that targets rodent populations by using nonlethal methods to restrict fertility. DIY Pest Control is an online distributor of pest control products. Evolve targets the root cause of pest problems-rats' ability to rapidly reproduce.

09:02 EST Toro Corp. announces completion of sale of M/T Wonder Formosa - Toro announces that on November 16, 2023, the Company completed the previously announced sale of the M/T Wonder Formosa, a 2006-built Handysize tanker, at a price of $18.0 million, by delivering the vessel to its new owner. The Company expects to record a net gain on the above-mentioned sale of approximately $9.0 million, excluding any transaction-related costs, during the fourth quarter of 2023.

09:01 EST Emerson Electric invests in Frugal Technologies - Emerson has made a strategic investment in Frugal Technologies, a Danish-based company that offers fuel optimization technologies that reduce energy use and emissions in shipping fleets. Frugal's cloud-based propulsion optimization software uses AI technology to collect data related to dynamic conditions such as weather, cargo load and propulsion and develop optimal engine models for ships. Frugal estimates its propulsion solutions generate savings of up to 15% in fuel consumption.

08:55 EST Quest Diagnostics partners with Universal DX for colorectal cancer blood test - Quest Diagnostics announced a strategic collaboration with Universal DX, a biotech company on a mission to transform cancer into a curable disease, designed to improve colorectal cancer screening in the United States. Under the commercial agreement between UDX and Quest, Quest plans to perform and provide clinical laboratory services to providers and patients in the United States based on UDX's Signal-C, an advanced colorectal cancer screening blood test, assuming premarket approval of the test in the U.S. To support a submission to the FDA for premarket approval, UDX will enroll patients in a 15,000-patient study involving more than 100 investigator sites to develop clinical evidence for the test. Assuming FDA approval, Quest will have exclusive rights to provide clinical laboratory services in the U.S. UDX also announced the initial closing of its series B financing of approximately $70M from investors, including Quest Diagnostics.

08:53 EST Toyota Motor Credit ordered by CFPB to pay $60M for illegal lending - The Consumer Financial Protection Bureau ordered Toyota Motor Credit Corporation to pay $60M in consumer redress and penalties for operating an illegal scheme to prevent borrowers from cancelling product bundles that increased their monthly car loan payments. The company withheld refunds or refunded incorrect amounts on the bundled products and knowingly tarnished consumers' credit reports with false information. The CFPB is ordering Toyota Motor Credit to stop its unlawful practices, pay $48M to harmed consumers, and pay a $12M penalty into the CFPB's victims relief fund. "Toyota's lending arm illegally withheld refunds, made borrowers run through obstacle courses to cancel unwanted services, and tarnished their credit reports," said CFPB Director Rohit Chopra. "Given the growing burdens of auto loan payments on Americans, we will continue to pursue large auto lenders that cheat their customers." Reference Link

08:45 EST MasterCard joint venture approved for domestic payments processing in China - Mastercard announced that its joint venture entity, Mastercard NUCC Information Technology, has received formal approval from the People's Bank of China, or PBOC, and the National Administration of Financial Regulation, or NAFR, to commence domestic bankcard clearing activity in China.

08:40 EST Staffing 360 receives Nasdaq notice related to non-timely filing Q3 form 10-Q - Staffing 360 Solutions reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q with the Securities and Exchange Commission, SEC, for the period ended September 30, 2023. Pursuant to the letter, The Nasdaq Hearings Panel will consider the late filing in their decision regarding the Company's continued listing on The Nasdaq Capital Market. Staffing 360 has until December 22, 2023 to present its views in writing with respect to the filing deficiency. With the exception of the 2023 third quarter filing, all of the Company's filings with the SEC are up to date. Staffing 360 Solutions said it expect to file the outstanding 2023 third quarter Form 10-Q by the end of this year.

08:38 EST Atossa announces full enrollment of Phase 2 Karisma-Endoxifen trial - Atossa Therapeutics announced that it has reached full enrollment in the Company's Karisma-Endoxifen clinical trial, the 240-person Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density, MBD. Participants have been randomized to placebo, 1 mg, and 2 mg daily doses of (Z)-endoxifen and will be treated for six months, over the course of which mammograms are conducted to measure reduction in MBD. MBD change is used as a proxy for therapy response. "We are excited that the Karisma-Endoxifen study is fully enrolled and look forward to seeing data from the trial in the second half of 2024," said Dr. Steven Quay, Atossa's President and Chief Executive Officer. "While significant progress has been made in breast cancer treatment, the same cannot be said about breast cancer prevention, particularly in high-risk women. (Z)-endoxifen is currently being studied in two populations that are at high risk of developing breast cancer, women with elevated breast density and women with ductal carcinoma in situ. Both diagnoses are strong, independent predictors of breast cancer risk that we feel are modifiable with (Z)-endoxifen."

08:38 EST Dyadic International's C1 platform to be used to produce vaccines in Africa - Dyadic International applauds the signing of an agreement between Dyadic's African licensee, Rubic One Health and Afreximaxbank to fund the project preparatory facility for the manufacture of vaccines using Dyadic's C1 protein production platform in South Africa for the entire continent. In April 2023, Dyadic expanded its licensing agreement with Rubic, a South African-based company whose mission is to develop African-based solutions for the discovery, development, evaluation and manufacture of high-quality, cost-effective human and animal vaccines and therapeutic proteins using Dyadic's C1 expression platform for distribution primarily to the African market. The quest to produce affordable vaccines suited to humans and animals in Africa has taken a step closer to realization with the signing of the agreement between Rubic and Afreximaxbank.

08:35 EST AstraZeneca launches health-tech business Evinova - AstraZeneca launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery. This will reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas. Drawing on AstraZeneca's deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. The technologies have already been used in the successful delivery of multiple AstraZeneca-sponsored clinical trials in over 40 countries. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "The future of medicine development can be accelerated with digital solutions. We believe Evinova's combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions." ... To accelerate industry adoption and sustain and expand the global reach of its digital products, Evinova is collaborating with Accenture and Amazon Web Services. Evinova will combine clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology spanning strategy and development, digital product development, data science and AI, user experience design and behavioural science. In addition to digital solutions, Evinova will offer custom scientific solutions, including remote patient monitoring and novel endpoint solutions, as well as trial design and consulting services.

08:33 EST Alpha Tau submits to Japanese PMDA for pre-market approval of Alpha DaRT - Alpha Tau Medical announced that Japan's Pharmaceuticals and Medical Devices Agency, PMDA, has accepted Alpha Tau's submission requesting shonin pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer, following multiple pre-submission consultation meetings with the PMDA per common practice in Japan. This submission is based upon Alpha DaRT's clinical trial results in Japan which exceeded the target endpoints for safety and efficacy in patients with recurrent head and neck cancer. Uzi Sofer, CEO of Alpha Tau, noted, "We identified Japan as an important strategic market and initiated a local clinical trial early on in our clinical development, and we are excited that this trial has not only met but exceeded its endpoints. We are working on all necessary preparations ahead of potential approval and commercialization, while continually considering other indications for initiating clinical trial investigation in Japan based on the specific patient needs there."

08:32 EST Kyle Vogt resigns as CEO of GM's Cruise unit - Kyle Vogt announced via X, the platform formerly known as Twitter, that he has resigned from his position as CEO of GM's Cruise unit. He said: "The last 10 years have been amazing, and I'm grateful to everyone who helped Cruise along the way. The startup I launched in my garage has given over 250,000 driverless rides across several cities, with each ride inspiring people with a small taste of the future. Cruise is still just getting started, and I believe it has a great future ahead. The folks at Cruise are brilliant, driven, and resilient. They're executing on a solid, multi-year roadmap and an exciting product vision. I'm thrilled to see what Cruise has in store next! As for what's next for me, I plan to spend time with my family and explore some new ideas. Thanks for the great ride!" Reference Link

08:31 EST Catheter Precision announces conclusion of inaugural VIVO cases in Croatia - Catheter Precision has disclosed the successful conclusion of the inaugural VIVO cases in the region of South-Eastern Europe. VIVO, the Company's innovative 3D non-invasive imaging system, is used pre-procedurally to identify areas of interest for ventricular ablation and aid in pre-procedure planning to reduce procedure time and aid in procedural accuracy. VIVO was assessed during four ventricular ablation procedures at Dubrava University Hospital in Zagreb, Croatia.

08:30 EST Enfusion appoints Neal Pawar as COO - Enfusion announced that it has appointed Neal Pawar to serve as Enfusion's COO effective November 27. Pawar will play a key role in shaping the next phase of Enfusion's business strategy and establishing operational management practices. Most recently, Pawar was the COO and later the CEO of Qontigo.

08:26 EST Wearable Devices completes first phase of deployment project with glasses OEM - Wearable Devices announced the successful completion of the first phase of a deployment project with a leading extended reality smart glasses original equipment manufacturer. In completing this first phase of testing, the Company has satisfied certain criteria outlined in a memorandum of understanding between Wearable Devices and the OEM for deployment of Wearable Devices' touchless technology into the OEM's product suite. The Company is currently collaborating with the OEM on customizing the user experience and interface as it relates to other solutions such as smartwatches and other wearable devices.

08:20 EST Information Services achieves ISO/IEC 27001 certification - Information Services Corporation announced the Company and its subsidiaries, ESC Corporate Services, Enterprise Registry Solutions Limited, Reamined Systems and UpLevel have achieved ISO/IEC 27001 certification. ISO/IEC 27001 is an internationally recognized standard for managing information security.

08:18 EST Worksport advances COR battery power generator system - Worksport announces that its groundbreaking COR battery system has officially transitioned into the Test Phase. This significant progression marks the beginning of intensive testing, anticipating a battery solution that is resilient, durable, and perfectly suited to the diverse challenges of today's dynamic environments. The Company's COR system can be used both within a pickup truck bed and independently without a pickup once it is released. With a commitment to quality, toughness and innovation, Worksport's Test Phase will see the COR battery system undergo: Performance evaluations in extreme heat and cold climates. Rigorous terrain trials including rough landscapes and standard road conditions. Examinations in humidity, vertical drops, as well as splash water and spray situations. Full-power performance assessments over extended durations. Shock tests to account for unforeseen events. "As we step into this crucial phase, we're not just testing a battery, we're challenging the conventions of what's possible. Our dedicated team is committed to delivering a product that resonates with the promise of uncompromising quality and durability, and unmatched performance. This product could be in the vehicles, homes and businesses of millions around the world. It simply needs to be the best." commented CEO Steven Rossi.

08:17 EST Verb Technology expands vendor acquisition with 15 more retailers - Verb Technology Company announces 15 more new vendors have joined the MARKET.live platform, upping the new vendor count to 35 in less than 30 days. The recent completion of the Company's tech integrations with the ecommerce solutions powering thousands of vendors' existing ecommerce stores are expected to continue drive demand from retailers eager to create new and additional distribution channels and affiliate relationships through MARKET.live. Retailers and creators that join MARKET.live have the ability to broadcast livestream shopping events simultaneously on numerous social media channels, as well as on MARKET.live, reaching exponentially larger audiences.

08:15 EST Voip-Pal.com defeats Ex PArte reexamination challenge against patent - VoIP-Pal.com has received notice of the USPTO's intent to issue an Ex Parte Reexamination Certificate for U.S. Patent 10,218,606. According to the notice, the USPTO has not only confirmed the patentability of the 31 claims that were originally challenged, but in addition, the USPTO also affirmed the patentability of 8 newly presented claims, which the Company believes further strengthen the '606 patent. The '606 patent covers methods and equipment for routing communications including video and voice calls within a communication system that associates user devices with particular network elements or nodes.

08:13 EST Constellium appoints Daniel Cooper to International Scientific Council - Constellium marks the 10th anniversary of its International Scientific Council. Established in 2013, the ISC has played a pivotal role in guiding Constellium's research and development endeavors, fostering innovation, supporting Constellium's sustainability targets, and addressing key challenges in the ever-evolving landscape of materials science. As part of the 10th anniversary celebration, Constellium is pleased to announce the appointment of Dr. Daniel Cooper, Assistant Professor of Mechanical Engineering at the University of Michigan, to its esteemed International Scientific Council.

08:10 EST iCAD, CancerIQ announce partnership to integrate AI-enabled technology - iCAD and CancerIQ announced a new partnership to create a best-in-class breast health care solution. The partnership will provide a seamless way to uniquely inform physicians and patients of cancer risk, identify breast cancer at earlier stages, when treatments work best, and increase patient adherence to their personalized care plans. Together, these solutions will combine elements from iCAD's artificial intelligence-enabled ProFound Breast Health Suite with CancerIQ's software and services, giving users a 2.4x more accurate prediction of breast cancer risk by combining AI-informed 1- or 2-year risk with lifetime risk, as well as a unique care management and patient activation workflow solution proven to more than double adherence to payer-supported supplemental screening recommendations. "This partnership will streamline how patients and physicians use our collective health data to schedule preventative screenings and manage breast health care in a way that will save lives," said Dana Brown, president and CEO of iCAD. "We look forward to a long-term relationship with CancerIQ that will create meaningful, actionable information in terms of proactive and personalized care benefiting both medical providers and the patients they serve." The partnership aims to combine CancerIQ's lifetime risk score and genetic risk data with iCAD's ProFound Density assessment score and ProFound Risk, the only AI-informed short-term cancer risk assessment that offers the industry's highest AUC for providing a one-year future risk estimation based on a 2D or 3D screening mammogram.

08:09 EST Dare Bioscience, Premier Research extend strategic partnership - Dare Bioscience and Premier Research International announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclusive basis contract research organization, CRO, services within the United States to support the clinical development of Dare's reproductive health portfolio. The agreement was originally established with Health Decisions, Inc., which was acquired by Premier Research in 2021. "In 2020, Dare and Premier Research conducted a successful Phase 3 clinical study of XACIATO vaginal gel 2% despite the challenges posed by a global pandemic. As we approach the start of the pivotal clinical study of Ovaprene, we are excited to reaffirm our strategic partnership with Premier Research and leverage its deep expertise in the clinical development of women's health products, including contraception," said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. "Dare is committed to advancing a portfolio of differentiated product candidates that address meaningful unmet needs in women's health in a timely and cost-efficient manner. This extended partnership has the potential to benefit multiple Dare programs, including those outside of reproductive health, such as the planned Phase 3 study of Sildenafil Cream, 3.6%, through the combination of commitment, clinical development expertise and cost savings." Under the terms of the extended agreement, Premier Research will continue to be Dare's exclusive provider of CRO services within the United States for all of Dare's reproductive health product candidates for another three-year period. In exchange for that CRO exclusivity, Premier Research will continue to provide attractive pricing structures, clinical expertise, an extensive site network, relationships with key opinion leaders and investigators, and a core team of personnel dedicated to supporting all of Dare's development programs covered by the agreement.

08:07 EST NV5 Global awarded $17M in New Jersey utility contracts - NV5 Global announced that it been awarded $17M in contracts to support utility projects in New Jersey. NV5 has been awarded a two-year, $12 million contract by a New Jersey gas utility to provide comprehensive design, procurement, and construction inspection services on various improvement projects. NV5 has also secured a three-year, $5 million contract to provide utility technical support and utility management solutions for the New Jersey Department of Transportation. "NV5's expertise in utility infrastructure development continues to be in high demand as investments in essential infrastructure drive improvements to the nation's electric and gas grid," said Dickerson Wright, PE, Chairman and CEO of NV5. "We are dedicated to contributing to the ongoing development of safe and reliable utility services, and these projects are expected to contribute to the increased organic growth of NV5."

08:06 EST Applied Digital announces Reed elected as independent director - Applied Digital (APLD) announced Kate Reed was elected as an independent director on its Board of Directors on November 9, 2023. Kate Reed is a technology industry veteran with experience in leading and developing teams across several key departments at IBM Corporation (IBM) from 2014 to 2023.

08:05 EST SaverOne 2014 announces pilot project with Tecne - SaverOne 2014 announced a strategically important pilot project with Tecne, the engineering company of Gruppo Autostrade per l'Italia, which is one of Europe's leading concessionaries for the construction and management of toll motorways, responsible for 3,000 km of road network in Italy. The pilot will involve the integration of SaverOne's Driver Distraction Prevention System into an initial 10 vehicles within Tecne Autostrade's fleet, which encompasses approximately 3,000 vehicles, signifying strong potential for SaverOne. This new pilot project with Tecne aligns with SaverOne's strategy to significantly broaden its presence in European markets. It follows the recent strategic appointment of Mr. Tal Yihie as Italian Country Partner, the new distribution agreement with Milan-based GVZ, as well as SaverOne's MOU and ongoing work with Italian-based OEM Iveco, all of which have enhanced SaverOne's growth and sales strategy in the region.

08:05 EST Ascendis Pharma announces EC approval of YORVIPATH - Ascendis Pharma announced that the European Commission, EC, has granted marketing authorization for YORVIPATH as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is a prodrug of parathyroid hormone administered once daily. Ascendis plans its first European Union launch of YORVIPATH in January 2024 in Germany. The EC approval follows the positive opinion adopted on September 14, 2023 by the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending approval of YORVIPATH. "By focusing on patient need and using science to drive our decisions, we have brought YORVIPATH - our second approved TransCon product - from concept through EU marketing authorization in only eight years and we are preparing to launch it in Germany this coming January," said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. "Knowing the urgent need that many patients and physicians have expressed for new treatment options, we will continue our work to make YORVIPATH widely available."

08:04 EST Onfolio subsidiary Vital completes launch of pocket inhaler product - Onfolio announces that its molecular hydrogen supplement subsidiary Vital Reaction successfully launched an innovative new pocket inhaler "Kencos" at the end of October. "One of the keys for growth of Vital Reaction is to launch new products, as you would expect with any eCommerce brand. Kencos has a mass appeal as an alternative to vaping or smoking for those wishing to quit. It was great to see the team at Vital Reaction, lead by Shaun Thresher, bring the product to market and have a successful launch," said Onfolio CEO Dom Wells.

08:03 EST VCI Global signs letter of intent to ac quire AI platforms from Playstack - VCI Global announced that it has signed an agreement with Playstack, a games developer and publisher based in the UK, to acquire the IP and assets of Playstack's unique AI based-AdTech platforms. The platform uses AI alongside gamification of digital marketing assets and new disruptive technologies, such as augmented reality to maximize brand engagements on mobile with global applications across corporate, consumer and large audience event opportunities. These platforms will significantly enhance VCIG's customer engagement and monetization, and act as the central conduit in its digital engagement strategy and growth plans, allowing VCIG to collect valuable customer data on spending behaviors and insights such that VCIG will drive consumer activations in its newly partnered businesses with hotels and other related organizations. "The integration of these AI brand engagement platforms by VCIG is a creative and innovative digital mechanism that will not only help VCIG drive user engagement, retention and purchasing, but also enhance our technology offering, enticing additional users and brands to engage with VCIG. It uniquely taps into the current consumer interest in AI and the Metaverse, allowing users to engage in a gamified world with brands at its core. We will be able to leverage the additional functionality as it provides valuable insights for tracking consumer behavior and a consumer experience unlike that provided by other media platforms. Focused on data driven customization of user and brand interaction, VCIG will offer a vast new digital engagement vertical in brand management, making the platform a measurable and transparent marketing tool, a marketer's dream," said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.

08:01 EST Tracon announces license of product development platform for $3M - TRACON Pharmaceuticals announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment. "We are excited to announce the first license of our PDP to a company that recognizes the value of internalizing its clinical operations to reap the benefits of CRO-independent clinical trial implementation that we enjoy at TRACON," said Charles Theuer, M.D., Ph.D., TRACON's Chief Executive Officer. "We are now in a position to widely license our PDP to allow clinical stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines." Under the terms of the Agreement, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical stage biotech company for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals.

07:47 EST Stryve Foods expands distribution of Vacadillos brand - Stryve Foods (SNAX) announces the nationwide distribution of its Vacadillos brand at Albertsons Companies (ACI) stores. Shoppers can now find Vacadillos products in the meat snack aisle of their local Albertsons Companies stores, making it easier than ever to incorporate the Company's protein-packed, flavorful snacks into their daily routine.

07:40 EST Marimed closes $58.7M debt refinancing - MariMed closed a $58.7 million secured credit facility with a U.S. chartered bank on November 17, 2023. Highlights of the refinancing deal include: A 10-year, $58.7 million Construction to Permanent Commercial Real Estate Mortgage loan. Interest at a lower fixed rate. After the first five years, the rate will be reset for the remaining 5 years. Interest only payments for the first 12 months. After the first 12 months, payments will be based on a 20-year amortization schedule. The loan is secured solely by the Company's Maryland and Massachusetts operating assets and real estate holdings. The Company's other operating assets and key brands such as Betty's Eddies and Nature's Heritage are now unencumbered with the payoff of the Chicago Atlantic term loan. The terms of the transaction do not include warrants or other equity or dilutive instruments. The loan proceeds were used to: Pay off the existing term loans with Chicago Atlantic and Bank of New England and a sellers note from the Ermont acquisition, which in the aggregate totaled approximately $46.8 million. The remaining funds will be held in escrow by the lender to complete the expansion of the Company's Hagerstown, Maryland cultivation facility. Any unused proceeds will be released to the Company after completion of the cultivation facility expansion.

07:38 EST SAB Biotherapeutics appoints Ellias to board of directors - SAB Biotherapeutics announced that Katie Ellias has been appointed to the Company's Board of Directors. Ellias serves as a Managing Director at the JDRF T1D Fund LLC, a venture philanthropy fund with approximately $200 million in assets, including an investment in SAB.

07:34 EST Scinai Immunotherapeutics regains compliance with stockholders' equity rule - Scinai Immunotherapeutics received formal notification from Nasdaq that the company has regained compliance with Nasdaq listing rules regarding minimum stockholders' equity. Nasdaq's determination that the company complies with Listing Rule 5550(b) which requires listed companies to maintain a minimum $2.5M in stockholders' equity, is based on the content of the company's Form 6-K dated November 13. Nasdaq also indicated that if the company does not evidence such compliance in its next periodic report, Nasdaq may provide notification to the company that it may be subject to delisting, at which time the company may appeal the determination to a Hearings Panel. The Company expects this new WACC to be incorporated in the company's financial statements for the year 2023. A higher WACC is expected to lower the NPV of long-term liabilities.

07:32 EST Ameresco to construct 50MW battery energy storage system with SVP - Ameresco has announced that it will construct a battery energy storage system, or BESS, of up to 50-megawatts,or MW, to provide Silicon Valley Power, or SVP, additional local area capacity for electrical system reliability and flexibility. The BESS, named Kifer Energy Storage, will be installed adjacent to the existing Kifer Receiving Station within SVP's service territory. The Ameresco owned asset, which is scheduled to begin construction in mid-2024, will mark the beginning of a 25-year lease and Energy Storage Agreement with the City of Santa Clara. Ameresco will develop, own, and operate the BESS, while SVP will supply the charging energy. With a maximum energy capacity of up to 200 megawatt-hours, or MWh, the BESS will efficiently acquire surplus renewable electricity and provide a clean and reliable resource to integrate renewables, decrease reliance on gas-fired generation, and mitigate greenhouse gas, or GHG, and criteria air pollutant emissions.

07:32 EST Zevra Therapeutics completes acquisition of Acer Therapeutics - Zevra Therapeutics announced the completion of its acquisition of Acer Therapeutics which marks a significant step forward in executing Zevra's strategy to become a leader in developing and commercializing treatments for rare diseases and furthers the Company's commitment to supporting patient communities with limited or no existing therapeutic options. As previously announced on August 31, 2023, the capital-efficient transaction included approximately 2.96 million shares of Zevra stock and contingent value rights issued in exchange for all outstanding shares of Acer. The CVRs represent the right to receive up to $76 million payable upon the achievement of certain regulatory and net sales milestones, net of the amount payable, if any, to SWK Funding LLC, a former warrantholder of Acer. In addition, immediately prior to the signing and announcement of the merger agreement, Zevra purchased Acer's senior secured debt for a combination of cash, Zevra stock and notes valued at $28.5 million as a condition of entering into the merger agreement with Acer. "Today's acquisition marks an exciting milestone for Zevra as we advance our mission to deliver therapies to the rare disease community," said Neil McFarlane, President and Chief Executive Officer of Zevra. "With our combined resources, expanded portfolio, and expert capabilities, we have the opportunity to make a tremendous impact on the lives of people with serious rare diseases. We are excited about the opportunities ahead for patients and remain focused on executing our strategic priorities to create long-term shareholder value."

07:18 EST Signal Gold announces $2M private placement - Signal Gold proposes to complete a non-brokered private placement to raise gross proceeds of up to $2,000,000. The Offering will consist of up to 1,266,666 units of the Company at a price of $0.15 per Unit, and up to 10,775,000 "flow-through" units of the Company at a price of $0.17 per FT Unit. Each Unit will consist of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each FT Unit will consist of one Common Share to be issued as a "flow-through share" as defined in subsection 66 of the Income Tax Act and one-half of one Warrant, to be issued on a non-flow-through basis. The Company is pleased to also announce that it has completed a first tranche of the Offering for aggregate gross proceeds of $1,320,016, pursuant to which the Company issued 7,764,800 FT Units. The gross proceeds from the Offering will be primarily used to advance growth exploration and permitting activities at the Goldboro Project and for working capital and general corporate purposes. Each Warrant entitles the holder thereof to purchase one common share of the Company at a price of $0.225 for a period of 18 months following the closing date of the applicable tranche of the Offering. The Warrants contain an acceleration clause whereby, after the expiration of the statutory hold period, if the common shares of the Company trade at a volume weighted average price of $0.30 or more for 10 consecutive trading days, the Company has the right to accelerate the exercise period to a period ending at least 30 days from the date that notice of such acceleration is provided to the holders of the Warrants.

07:15 EST DavidsTea expands wholesale channel into U.S. - DAVIDsTEA announced its initial expansion into the U.S. wholesale market. DAVIDsTEA recently launched four flavours of premium tea sachets at 150 Stop & Shop supermarket stores of the 400-plus locations in the northeastern U.S. This regional chain of grocery stores operates throughout Massachusetts, Connecticut, Rhode Island, New York and New Jersey. On a smaller scale, the Company recently introduced five flavours at Roche Bros. supermarkets. This family-owned business operates in 20 locations across Massachusetts.

07:12 EST PyroGenesis announces receipt of second US $378,900 milestone payment - PyroGenesis Canada announces that, further to its press release dated September 12, 2023, it has received the second milestone payment of approximately US $378,900. This payment is associated with the engineering phase, of the plasma torch contract with a U.S. corporation, geared to destroy Perfluoroalkyl and Polyfluoroalkyl Substances. The name of the Client will remain anonymous for confidentiality reasons. The engineering phase is nearing completion representing a key milestone in PyroGenesis' development of a state-of-the-art plasma torch technology suitable for PFAS removal. PyroGenesis is on track to begin the manufacturing process over the coming weeks. The Company expects to complete the manufacturing phase by the end of the second quarter of 2024. "We are very pleased with the progress to date in developing this new state-of-the-art plasma torch, and look forward to the upcoming completion of the manufacturing phase," said P. Peter Pascali of PyroGenesis. "The eventual completion of the manufacturing phase will mark an important milestone in PyroGenesis' stated goal to advance PFAS eradication using state-of-the-art plasma torch technology. Today brings us one step closer to delivering a PyroGenesis based solution that addresses critical environmental challenges, reinforcing our unwavering commitment to sustainable innovation."

07:10 EST C4 Therapeutics appoints Hughes to board of directors - C4 Therapeutics (CCCC) announced the appointment of Owen Hughes to its board of directors. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance. Hughes most recently served as co-founder and chief executive officer of Cullinan Oncology (CGEM)

07:08 EST KVH Industries announces several fleets turn to KVH for content services - Fleets such as TMS Gas Cardiff of the UK, Nereus Shipping SA in Greece, Tomini Transports LLC in Dubai, and GFS Fleet Management in Dubai have turned to KVH Industries for content services designed to enhance crew well-being. Content options range from daily local news to blockbuster films, popular TV programming, real-time sports statistics, music, and social engagement through karaoke and other content. "It's vital to remember that commercial vessels aren't simply floating offices and warehouses but homes for millions of seafarers from diverse cultures," explains Jamie Airs, KVH's Global Content Sales Manager. "Access to news, sports, entertainment, and social interaction all contribute to the positive mental health of crews at sea. Our KVH Link suite of crew content services delivers best-in-class content in various languages while offering an exciting, entertaining experience for the crew on laptops, personal devices, and TVs."

07:07 EST Plus Therapeutics reports interim ReSPECT-GBM Phase 2 trial data - Plus Therapeutics announced data from the ongoing ReSPECT-GBM Phase 2 trial evaluating the Company's lead radiotherapeutic, rhenium obisbemeda, for the treatment of recurrent glioblastoma at the Society for NeuroOncology 28th Annual Meeting held November 15-19, 2023 in Vancouver, Canada. The Company is hosting a virtual key opinion leader webinar to discuss the data today at 10:00 am ET. Key Highlights from the ReSPECT-GBM Phase 2 Trial ReSPECT-GBM is an ongoing, first-in-human, open-label, Phase 1/2 study investigating dose escalation and other delivery parameters to determine the maximum tolerated dose, maximum feasible dose, safety, and efficacy of rhenium obisbemeda in recurrent adult glioma. The primary objective of the Phase 2 study is to assess overall survival following rhenium obisbemeda administration. As of November 14, 2023, 15 patients with rGBM have been treated with rhenium obisbemeda at a dose of 22.3 mCi delivered directly to the tumor by Convection Enhanced Delivery. In 15 treated patients, mOS is 13 months. Currently, 9 out of the 15 treated patients remain alive. Median PFS is 11 months. The average percent of treated tumor across all 15 patients was 87.2% at 120 hours, with 13/15 patients receiving greater than or equal 70% tumor volume coverage by the drug and greater than or equal to100 Gy absorbed dose to the tumor. Advanced longitudinal imaging analysis supports the observed efficacy signal of rhenium obisbemeda. Rhenium obisbemeda continues to be generally safe and well tolerated, consistent with data accumulated in the Phase 1 trial.

07:07 EST Nevro's SCS system delivers long-term relief with spinal cord stimulation - Nevro announced the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain - NSRBP - multicenter randomized controlled trial in the Journal of Neurosurgery: Spine. The published 24-month data evaluated outcomes for NSRBP patients treated with Nevro's high-frequency spinal cord stimulation - SCS - system plus conventional medical management - CMM - versus CMM alone. The data show that patients in the high-frequency SCS arm experienced profound improvements in pain, function, and quality of life, plus reduced opioid use compared to the CMM arm at 24 months. The long-term data provides further evidence of the benefits of high-frequency SCS in managing patients with NSRBP. 81.6% of all patients who received a permanent implant were classified as pain responders - achieved greater than or equal to 50% pain relief - at 24 months, with 58.4% of patients classified as profound responders who achieved greater than or equal to 80% pain relief. Opioid usage was decreased or stopped in 62% percent of patients who were using opioids at baseline. No new safety signals were identified during the 24-month follow-up.

07:04 EST ProMIS Neurosciences doses first subjects in Phase 1a trial of PMN310 - ProMIS Neurosciences announced that the Company dosed the first subjects in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for Alzheimer's disease. "Initiation of this milestone study of PMN310 marks our transition to a clinical stage company. We are excited to bring our precision medicine approach into the clinic in hopes of developing better therapeutics for neurodegenerative diseases," said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. "During the third quarter, we raised more than $20 million through a private placement financing, which meaningfully strengthens our balance sheet and supports ProMIS through potentially value-creating milestones... Results from the Phase 1a study will facilitate dose selection for subsequent Phase 1b study in patients with Mild Cognitive Impairment due to AD and patients with mild AD. This study will leverage recent results from a third-party clinical study, which demonstrated that plasma and cerebrospinal fluid efficacy biomarkers can show a treatment response in as little as three months with oligomer-focused therapy. In addition, our Phase 1b study will provide important insights into the safety profile of PMN310, which we anticipate may differentiate PMN310 from other available and potentially disease-modifying treatments."

07:03 EST Agios announces clinical proof-of-concept Phase 2a trial of AG-946 - Agios Pharmaceuticals announced that clinical proof-of-concept has been achieved in the Phase 2a portion of a study of investigational pyruvate kinase activator AG-946 as a potential treatment for anemia in adults with lower-risk myelodysplastic syndromes. Four of the 10 patients with low transfusion burden achieved the transfusion independence endpoint, and one of the 22 patients treated in the study achieved the hemoglobin response endpoint in the 16-week treatment period. The safety profile observed was consistent with data reported in the healthy volunteer study. Based on the favorable efficacy data and positive benefit-risk profile in the Phase 2a core period, Agios intends to advance its clinical program evaluating AG-946 in LR-MDS by initiating the placebo-controlled Phase 2b portion of the study in mid-2024. "We are pleased with the results of the Phase 2a study, which underscore the potential of AG-946 to be a first-in-class, oral, safe and effective option for the treatment of anemia in adults with LR-MDS by improving red blood cell health through its unique mechanism of action. Regular blood transfusions are burdensome for patients. A meaningful reduction in transfusions allows patients to potentially decrease visits to the clinic and experience improved quality of life. We are grateful to all of the patients who participated in this trial, our collaborators, study investigators and advisors in the patient and clinical communities for their partnership in achieving this milestone, and we look forward to advancing the clinical program to Phase 2b," said Sarah Gheuens, M.D., Ph.D., chief medical officer and head of R&D at Agios. "Agios is proud to be the leader in PK activation with two distinct PK activators - AG-946 and mitapivat - that have the potential to be meaningful treatment options for a wide range of blood disorders and positively impact many patients' lives."

07:02 EST Hookipa Pharma announces FDA clearance of IND application for HB-500 - HOOKIPA Pharma announced that the Company has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter. Nature Partner Journals Vaccines recently published the joint-preclinical research by HOOKIPA and Gilead, which served as the foundation for the IND submission. The analyses published were conducted with a simian immunodeficiency virus model, commonly used in a preclinical setting as a surrogate to HIV. The data show that: Arenaviral therapeutic vaccination was well tolerated and generated robust, high-quality and durable immune responses in non-human primates; and, Arenaviral therapeutic vaccination significantly reduced SIV viral load and clinical illness in those animals compared to placebo. HB-500 is an alternating, 2-vector arenaviral therapeutic vaccine for the treatment of HIV. One vector is based on lymphocytic choriomeningitis virus as its arenaviral backbone; another vector is based on Pichinde virus. Both encode the same HIV antigens. The alternating 2-vector approach is designed to further focus the immune response against the target antigen.

06:57 EST Enlight Renewable subsidiary selected for solar project in California - Enlight Renewable announced that Country Acres Clean Power, an affiliate of its subsidiary Clenera Holdings, has entered into certain agreements in connection with a new project under development located in Placer County, California. The Project is expected to have an installed capacity of 392 MWdc / 344MWac of solar energy and 688 MWh of energy storage. The agreements include a busbar power purchase agreement with the Sacramento Municipal Utility District, a municipal electric utility serving Sacramento County and parts of Placer County, California. Under the PPA, Country Acres will sell the solar energy produced by the facility for a 30-year term and energy storage for a 20-year term. In addition to the executed PPA, Country Acres has also entered into an interconnection agreement with SMUD. Upon completion of the required permits, construction is expected to begin in 2024, with commercial operations commencing in 2026. The Project is expected to provide zero carbon electricity to approximately 80,000 homes annually.

06:53 EST Wallbox, Atlante partner to deploy EV fast-charging network in Southern Europe - Wallbox and Atlante have joined forces to develop new public charging points in Italy, France, Spain, and Portugal. Both companies have a long-standing commitment to promoting sustainability and technological innovation in the field of electric mobility and have now further strengthened their collaboration. The partnership with Wallbox will enable Atlante to speed up its ambitious project of installing 5,000 points of charge by 2025 and 35,000 by 2030, all of them 100% enabled by renewables and backed by storage and photovoltaic canopies, where possible. Atlante's fast-charging stations will be equipped with Wallbox's public charger Supernova, both in its 60 kW version and the latest 150 kW version. They will be strategically positioned along the primary transportation arteries linking Southern Europe, in strict compliance with the recently ratified legislation by the European Parliament. This legislation stipulates the requirement of establishing at least one charging point per 60 kilometers on the core road network of the European Union, and one for every 100 kilometers on the Trans-European network. Additionally, Atlante will install charging stations in parking lots and strategic urban areas.

06:42 EST Centrus Energy CEO Daniel Poneman to depart, Amir Vexler to succeed - Centrus Energy announced that Amir Vexler will succeed Daniel Poneman as CEO on January 1, 2024. Poneman joined Centrus on March 5, 2015. In October, Centrus inaugurated the first new U.S.-owned uranium enrichment plant to begin production in nearly 70 years and made its first delivery to the U.S. Department of Energy earlier this month. These achievements are reflected in the growth of the company's total market capitalization 20-fold since 2015 to more than $800M and returns to shareholders almost five times higher than the S&P 500.

06:32 EST Airbnb announces Ron Klain to join as Chief Legal Officer - Airbnb announced that Ron Klain will join the company as Chief Legal Officer. "Ron is a distinguished leader with more than four decades of experience across government and business, best known for his role as White House chief of staff during President Biden's first two years in office. Previously, Ron was chief of staff to then-Vice President Biden and to Vice President Al Gore at just 34 years old, making him the youngest chief of staff to a vice president in American history," the company stated. "Ron is both a big-picture strategic thinker and a highly skilled operator, and I'm thrilled he'll be a close advisor," said Airbnb co-founder and CEO, Brian Chesky.

05:29 EST Microsoft says Sam Altman, Greg Brockman joining to lead AI research - Microsoft CEO Satya Nadella said via X, "We remain committed to our partnership with OpenAI and have confidence in our product roadmap, our ability to continue to innovate with everything we announced at Microsoft Ignite, and in continuing to support our customers and partners. We look forward to getting to know Emmett Shear and OAI's new leadership team and working with them. And we're extremely excited to share the news that Sam Altman and Greg Brockman, together with colleagues, will be joining Microsoft to lead a new advanced AI research team. We look forward to moving quickly to provide them with the resources needed for their success."

05:22 EST Full Truck Alliance sees Q4 revenue up 18.2%-20.6%, consensus $317.38M - The company said, "The Company expects its total net revenues to be between RMB2.27 billion and RMB2.32 billion for the fourth quarter of 2023, representing a year-over-year growth rate of approximately 18.2% to 20.6%. These forecasts reflect the Company's current and preliminary views on the market and operational conditions, which are subject to change and cannot be predicted with reasonable accuracy as of the date hereof."

05:06 EST L&T Technology Services collaborates with Nvidia on AI for medical devices - L&T Technology Services (LTTS) has announced a collaboration with Nvidia (NVDA) to develop software-defined architectures for medical devices focused on endoscopy, which will enhance the image quality and scalability of products.